Compare Citius Pharmaceuticals Inc (CTXR) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Prudential PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 2117.5× Citius Pharmaceuticals Inc's market cap, and Prudential PLC pays a 2.33% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Prudential PLC for 119 Days on average.
| CTXR | PUK | |
|---|---|---|
Market Cap | $13.62M | $28.84B |
Volume | 132,438 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $1.82 | $33.61 |
52-Week Low | $0.48 | $23.54 |
Typical Hold Time | 17 Days | 119 Days |
Enterprise Value | $3.79M | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Prudential Public Limited Company (PUK) trades at $23.92, up 1.61% over 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39B in 2025 and a net income of $3.98B, with improving profitability margins and a low P/E of 8.4. Recent news highlights strategic shifts, including the sale of its Alexforbes stake and a focus on core markets.
The outlook is mixed: solid fundamentals and analyst 'Moderate Buy' consensus support upside, but technical weakness and earnings misses pose near-term risks. Key opportunities include capital return initiatives and cost savings; risks involve execution of strategic overhaul and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
